Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Skin and Connective Tissue Diseases

ClinicalTrials.gov lists 37,885 trials for Skin and Connective Tissue Diseases or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 523.

MeSH D017437 Skin and Connective Tissue Diseases C17
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 4,281 Phase 1/2 Phase 1/2 1,827 Phase 2 Phase 2 7,140 Phase 2/3 Phase 2/3 503 Phase 3 Phase 3 3,916 Phase 4 Phase 4 2,017 Not applicable Not applicable 9,820 Observational Observational 8,278 Phase 1 Phase 1 4,281 Phase 1/2 Phase 1/2 1,827 Phase 2 Phase 2 7,140 Phase 2/3 Phase 2/3 503 Phase 3 Phase 3 3,916 Phase 4 Phase 4 2,017 Not applicable Not applicable 9,820 Observational Observational 8,278

Trials per phase

2 more sections with rows

20 of the 37,885 trials are tagged with Skin and Connective Tissue Diseases itself; the rest are tagged with a narrower condition beneath it.

Get the Skin and Connective Tissue Diseases report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Skin and Connective Tissue Diseases trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 74 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Expanded access, Unknown)

Top of scale: 2,287

1990: 12 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 3, Phase 2 2, Phase 1/2 1) 1991: 22 trials (Observational 8, Not applicable 2, Phase 3 3, Phase 2/3 1, Phase 2 5, Phase 1/2 1, Phase 1 2) 1992: 19 trials (Observational 5, Not applicable 3, Phase 3 5, Phase 2 4, Phase 1 2) 1993: 23 trials (Observational 5, Not applicable 1, Phase 3 13, Phase 2 1, Phase 1/2 1, Phase 1 2) 1994: 37 trials (Observational 12, Not applicable 4, Phase 3 7, Phase 2/3 1, Phase 2 7, Phase 1/2 2, Phase 1 4) 1995: 57 trials (Observational 17, Not applicable 1, Phase 3 14, Phase 2/3 1, Phase 2 13, Phase 1/2 4, Phase 1 7) 1996: 89 trials (Observational 22, Not applicable 4, Phase 4 2, Phase 3 29, Phase 2 16, Phase 1/2 4, Phase 1 12) 1997: 114 trials (Observational 16, Not applicable 11, Phase 4 3, Phase 3 23, Phase 2/3 2, Phase 2 34, Phase 1/2 12, Phase 1 13) 1998: 131 trials (Observational 24, Not applicable 10, Phase 4 3, Phase 3 30, Phase 2/3 2, Phase 2 43, Phase 1/2 6, Phase 1 13) 1999: 176 trials (Observational 33, Not applicable 9, Phase 4 3, Phase 3 34, Phase 2/3 2, Phase 2 57, Phase 1/2 9, Phase 1 29) 2000: 254 trials (Observational 46, Not applicable 28, Phase 4 10, Phase 3 41, Phase 2/3 4, Phase 2 78, Phase 1/2 20, Phase 1 27) 2001: 271 trials (Observational 45, Not applicable 27, Phase 4 16, Phase 3 54, Phase 2/3 4, Phase 2 75, Phase 1/2 16, Phase 1 34) 2002: 350 trials (Observational 43, Not applicable 33, Phase 4 25, Phase 3 73, Phase 2/3 7, Phase 2 115, Phase 1/2 19, Phase 1 35) 2003: 458 trials (Observational 64, Not applicable 56, Phase 4 40, Phase 3 82, Phase 2/3 13, Phase 2 149, Phase 1/2 18, Phase 1 36) 2004: 616 trials (Observational 85, Not applicable 87, Phase 4 56, Phase 3 109, Phase 2/3 12, Phase 2 181, Phase 1/2 30, Phase 1 56) 2005: 759 trials (Observational 125, Not applicable 96, Phase 4 56, Phase 3 120, Phase 2/3 14, Phase 2 225, Phase 1/2 40, Phase 1 83) 2006: 894 trials (Other 2, Observational 166, Not applicable 114, Phase 4 76, Phase 3 136, Phase 2/3 16, Phase 2 251, Phase 1/2 45, Phase 1 88) 2007: 1,018 trials (Observational 185, Not applicable 143, Phase 4 81, Phase 3 141, Phase 2/3 16, Phase 2 277, Phase 1/2 62, Phase 1 113) 2008: 1,113 trials (Observational 221, Not applicable 161, Phase 4 84, Phase 3 148, Phase 2/3 21, Phase 2 287, Phase 1/2 51, Phase 1 140) 2009: 1,177 trials (Other 3, Observational 242, Not applicable 202, Phase 4 93, Phase 3 155, Phase 2/3 21, Phase 2 270, Phase 1/2 65, Phase 1 126) 2010: 1,215 trials (Other 1, Observational 269, Not applicable 223, Phase 4 100, Phase 3 140, Phase 2/3 18, Phase 2 259, Phase 1/2 66, Phase 1 139) 2011: 1,236 trials (Other 1, Observational 275, Not applicable 226, Phase 4 86, Phase 3 150, Phase 2/3 22, Phase 2 265, Phase 1/2 42, Phase 1 169) 2012: 1,290 trials (Observational 309, Not applicable 281, Phase 4 66, Phase 3 161, Phase 2/3 25, Phase 2 249, Phase 1/2 52, Phase 1 147) 2013: 1,332 trials (Observational 271, Not applicable 308, Phase 4 82, Phase 3 161, Phase 2/3 12, Phase 2 272, Phase 1/2 50, Phase 1 176) 2014: 1,410 trials (Other 1, Observational 305, Not applicable 357, Phase 4 62, Phase 3 164, Phase 2/3 20, Phase 2 259, Phase 1/2 66, Phase 1 176) 2015: 1,592 trials (Observational 334, Not applicable 415, Phase 4 83, Phase 3 174, Phase 2/3 12, Phase 2 294, Phase 1/2 84, Phase 1 196) 2016: 1,648 trials (Observational 318, Not applicable 485, Phase 4 99, Phase 3 137, Phase 2/3 10, Phase 2 304, Phase 1/2 81, Phase 1 214) 2017: 1,651 trials (Other 1, Observational 345, Not applicable 509, Phase 4 63, Phase 3 140, Phase 2/3 23, Phase 2 289, Phase 1/2 92, Phase 1 189) 2018: 1,757 trials (Observational 397, Not applicable 510, Phase 4 88, Phase 3 178, Phase 2/3 34, Phase 2 260, Phase 1/2 84, Phase 1 206) 2019: 1,872 trials (Observational 455, Not applicable 570, Phase 4 77, Phase 3 135, Phase 2/3 14, Phase 2 319, Phase 1/2 92, Phase 1 210) 2020: 1,792 trials (Observational 454, Not applicable 543, Phase 4 85, Phase 3 114, Phase 2/3 18, Phase 2 287, Phase 1/2 88, Phase 1 203) 2021: 2,160 trials (Observational 566, Not applicable 669, Phase 4 93, Phase 3 157, Phase 2/3 22, Phase 2 343, Phase 1/2 91, Phase 1 219) 2022: 2,222 trials (Observational 546, Not applicable 721, Phase 4 105, Phase 3 174, Phase 2/3 31, Phase 2 304, Phase 1/2 94, Phase 1 247) 2023: 2,180 trials (Observational 539, Not applicable 727, Phase 4 93, Phase 3 180, Phase 2/3 32, Phase 2 297, Phase 1/2 107, Phase 1 205) 2024: 2,223 trials (Observational 517, Not applicable 801, Phase 4 79, Phase 3 165, Phase 2/3 24, Phase 2 286, Phase 1/2 107, Phase 1 244) 2025: 2,287 trials (Observational 556, Not applicable 740, Phase 4 89, Phase 3 176, Phase 2/3 20, Phase 2 332, Phase 1/2 100, Phase 1 274)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 2,046
2025 2,287
2024 2,223
2023 2,180
2022 2,222
2021 2,160
2020 1,792
2019 1,872
2018 1,757
2017 1,651

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 2,500 trials starting in 2026 and about 2,300 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 10 percent and ran about 4 percent high against the count later registered; forecasts made before the year began were off by about 25 percent and ran about 15 percent low against the count later registered, and had about 7 percent more error than repeating last year's count. The part-way figures are from forecasts that used a multiple fitted only on earlier years. A stricter check that trains only on older years did not support adding planned starts for conditions of this size: it ran about 6 percent high against the count later registered. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 3,659 trials still running at the 2026-10-09 snapshot; registered median of 24 months across 23,247 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Skin and Connective Tissue Diseases trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 4,281
Phase 1/2 1,827
Phase 2 7,140
Phase 2/3 503
Phase 3 3,916
Phase 4 2,017
Not applicable 9,820
Observational 8,278
Expanded access 101
Unknown 2

How many Skin and Connective Tissue Diseases trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 1,684
Recruiting 4,461
Enrolling by invitation 261
Active, not recruiting 1,948
Available 34

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Skin and Connective Tissue Diseases trials? (9)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 523
Pfizer 504
Novartis Pharmaceuticals 493
Hoffmann-La Roche 453
AstraZeneca 289

Showing 5 of 9 sponsors.

Start your 14-day trial Email me all 9 sponsors as a PDF

Which drugs are being tested for Skin and Connective Tissue Diseases? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 722
(nab)-paclitaxel 583
TRASTUZUMAB 547
PEMBROLIZUMAB 474
"Capecitabine" 344

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
HD- Methotrexate (MTX) 424
Docetetaxel 391
or carboplatin 315
Letrozol (Femara, Novartis) 302
Doxorubicine 284

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Skin and Connective Tissue Diseases trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 7,922 1,317
Febrile neutropenia 3,807 514
Pyrexia 3,798 775
Neutropenia 3,455 456
Vomiting 3,237 891

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Sub-conditions in MeSH (2)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: publications, prevalence, and rare-disease identity.

Browse all condition evidence pages